Sclerotherapy using air- or CO2-O2-foam. Post-approval study;Die sklerotherapie mit luft- oder CO2-O2-schaum. Anwendungsbeobachtung

Phlebologie

Volumn 41, Issue 2, 2012, Pages 77-88

  Hesse, Gottfried ^a   Breu, F X ^b   Kuschmann, A ^b   Hartmann, K ^c   Salomon, N ^a  

^a Venenzentrum Freiburg ^*  (Germany)

^b NONE

^c Venenzentrum Freiburg   (Germany)

Author keywords

Air foam sclerotherapy; Efficiency; Side effects; Visual side effects

Indexed keywords

CARBON DIOXIDE; OXYGEN; POLIDOCANOL;

ARTICLE; BURNING SENSATION; CLINICAL EFFECTIVENESS; ECHOGRAPHY; FOAM SCLEROTHERAPY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MIGRAINE; MULTICENTER STUDY; OBSERVATIONAL STUDY; SCLEROTHERAPY; THROMBOSIS; VARICOSIS; VEIN OCCLUSION; VISUAL DISORDER;

EID: 84862146773     PISSN: 0939978X     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1621805     Document Type: Article

References (72)

1. Almeide JI. Ultrasound-guided foam sclerotherapy. Endovascular today 2010: 33-35.
2. Beckitt T et al. Air versus Physiological Gas for Ultrasound Guided Foam Sclerotherapy Treatment of Varicose Veins. Eur J Vasc Endovasc Surg 2011; 1e5.
3. Bessereau J, Genotelle N, Chabbaut C et al. Long-term outcome of iatrogenic gas embolism. Intensive care medicine 2010; 36(7): 1180-1187.
4. Bessereau J, Coulange M et al Iatrogenic gas embolism after foam sclerotherapy? Annales francaises d'anesthesie et de reanimation 2011; 13385-13385.
5. Blaise S et al. Ultrasound-Guided Sclerotherapy of the Great Saphenous Vein with 1% vs. 3% Polidocanol Foam: A Multicentre Double-Blind Randomised Trial with 3-Year Follow. Eur J Vasc Endovasc Surg 2010; 39(6): 779-786.
6. Breu FX et al. 2nd European Consensus Meeting on Foam Sclerotherapy 2006, Tegernsee Germany. Vasa 2008: 37, 71: 1.
7. Bush RG et al Major neurological events following foam sclerotherapy. Phlebology 2008: 23(4): 189-192.
8. Cabrera J et al. Treatment of venous malformations with sclerosant in microfoam form. Arch Dermatol. 2003: 139(11): 1409-1416. (Pubitemid 37433130)
9. Cabrera J et al. In :Mattassi R et al. (Eds.) Hemangiomas and vascular malformations. Heidelberg: Springer 2009; 171-179.
10. Cavezzi A et al. Foam sclerotherapy techniques: different gases and methods of preparation, catheter versus direct injection. Phlebology 2009: 24: 247-251.
11. Ceulen RPM et al. Microembolism during foam sclerotherapy of varicose veins. N Engl J Med 2008: 358; 1525-1526. (Pubitemid 351482767)
12. Coleridge Smith P. Chronic venous disease treated by ultrasound guides foam sclerotherapy. Eur J Vasc Endovasc Surg 2006: 32: 577-583.
13. Coleridge Smith P. Sclerotherapy and foam sclerotherapy for varicose veins. Phlebology 2009: 24: 260-269.
14. Christin F et al Paradoxical symptomatic air embolism after saline contrast transesophageal echocardiography. Echocardiography. N.Y.: Mount Kisco 2007: 24(8): 867-869.
15. Deichmann B et al. Apoplektischer Insult nach Sklerotherapie. Phlebologie 1995: 24: 148-152.
16. Deurzen B VAN, Ceulen RP et al. Polidocanol Concentration and Time Affect the Properties of Foam Used for Sclerotherapy. Dermatologic surgery 2011; 1-8.
17. Durandt TM et al. The safety of intravascular carbon dioxide and its use for roentgenologic visualization of intracardiac structures. Ann Int Med 1957; 47: 191-201.
18. Eckmann DM. Polidocanol for endovenous microfoam sclerosant therapy. Expert Opin Investig Drugs 2009; 18(12): 1919-1927.
19. Eklöf B, Rutherford RB, Bergan JJ et al. Revision of the CEAP classification for chronic venous disorders: consensus statement. J Vasc Surg 2004; 40(6): 1248-1252. (Pubitemid 40037299)
20. Forlee MV et al. Stroke after varicose vein foam injection sclerotherapy. J Vasc Surg 2006; 43(1): 162-164. (Pubitemid 43083525)
21. Frullini A et al. High production of endothelin after foam sclerotherapy: a new pathogenetic hypothesis for neurological and visual disturbances after sclerotherapy. Phlebology 2011:1-6.
22. Genotell N, Bessereau J AD. Is it necessary to revalue the risk of a gas embolism complicating an intervention with carbon dioxide insufflation? Answer elements. Annales françaises d'anesthèsie et de rèanimation 2008; 27: 756-757 .
23. Gillet JL et al. Side-effects and complications of foam sclerotherapy of the great and small saphenous veins: a controlled multicentre prospective study including 1,025 patients. Phlebology 2009; 24(3): 131-138.
24. Gillet JL et al. Pathophysiology of visual disturbances occurring after foam sclerotherapy. Phlebology 2010; 25: 261-266.
25. Gloviczki P. Invited commentary. J Vasc Surg 2011; 53(1): 137-138.
26. Guex J-J, Allaert F-A, Gillet J-L, Chleir F. Immediate and midterm complications of sclerotherapy: report of a prospective multicenter registry of 12,173 sclerotherapy sessions. Dermatologic surgery 2005: 31(2): 123-128. (Pubitemid 40990934)
27. Guex J-J. Complications and side-effects of foam Sclerotherapy. Phlebology 2009; 24: 270-274.
28. Guex J-J et al. The French Polidocanol Study on Long-Term Siede Effects: A Survey Covering 3,357 Patient Years. Dermatol Surg 2010; 36: 993-1003.
29. Jia X et al. Systematic review of the safety and efficacy of foam sclerotherapy for venous disease of the lower limb. Brit J Surg 2007; 94 (8): 925-936.
30. Habegger R et al Lethal air embolism during arthroscopy. J Bone Joint Surg 1989; 71-B: 314-316.
31. Hahn M et al. Late stroke after foam sclerotherapy. Vasa 2010; 39: 108-110.
32. Hamahata A et al. Outcomes of Ultrasound-Guided Foam Sclerotherapy for Varicose Veins of the Lower Extremities: A Single Center Experience. Dermatol Surg 2011; 37: 804-809.
33. Hamel-Desnos C et al. Liquid versus foam sclerotherapy. Phlebology 2009; 24: 240-246.
34. Hanisch F et al. Stroke following variceal sclerotherapy. Eur J Med Res. 2004; 9(5): 282-284.
35. Hartmann K. Reversible neurological deficit after foam sclerotherapy. Eur J Vasc Endovasc Surg 2009; 38(5): 648-649.
36. 2) digital subtraction angiography: 26-year experience at the University of Florida. Eur Radiol 1998; 8(3): 391-402.
37. Hlastala MP et al. Absorption of in vivo inert gas bubbles. Respir Physiol 1975; 24 (2):147-158.
38. Kas A et al. Cerebellar infarction after sclerotherapy for leg varicosities. Presse Med 2000; 29(35): 1935.
39. Künzlberger B, Pieck C, Altmeyer P SM. Migraine Ophthalmique liquid 1% polidocanol. Dermatol Surg 2006; 32: 1410-1413.
40. Leslie-Mazwi TM et al. Intra-arterial air thrombogenesis after cerebral air embolism complicating lower extremity sclerotherapy. Neurocrit Care 2009; 11: 247-250.
41. Linde Gas Therapeutics GmbH 85716 Unterschleißheim. http://www.linde-gastherapeutics.de. Fachinformation/Zusammenfassung der Merkmale des Arzneimittels
42. Liu FC et al. Hemodynamic changes caused by venous gas embolism in dogs: comparisons among air, carbon dioxide and oxygen. Acta Anaesthesiol Sin 2001; 39(2): 71-76.
43. Ma RW et al.Three cases of stroke following peripheral venous interventions. Phlebology 2011; 26 (7): 280-284.
44. Maeseneer M De. The endovenous revolution. The Br J Surg 2011; 98(8): 1037-1038.
45. Morrison N et al. Comparisons of side effects using air and carbon dioxide foam for endovenous chemical ablation. J Vasc Surg 2008; 47(4): 830-836.
46. Morrison N et al. Foamsclerotherapy : Cardiac and cerebral monitoring. Phlebology 2009; 24: 252-259.
47. Morrison N et al. Incidence of Side Effects Using Carbon Dioxide-Oxygen Foam for Chemical Ablation of Superficial Veins of the Lower Extremity. Eur J Vasc Endovasc Surg 2010; 40 (3): 407-413.
48. Myers KA. Evaluation of published reports of foam sclerotherapy: what do we know conclusively? Phlebology 2009; 24(6): 275-280.
49. NICE Ultrasound-guided foam sclerotherapy for varicose veins Target date for publication of guidance: 2009 IPG ISBN 978-1-84936-065-4 N1978 1P .
50. O'Hare JL, Earnshaw JJ. The use of foam sclerotherapy for varicose veins: a survey of the members of the Vascular Society of Great Britain and Ireland. Eur J Vasc Endovasc Surg 2007; 34(2): 232-235. (Pubitemid 46995771)
51. Palm MD, Guiha IC, Goldman MP. Foam sclerotherapy for reticular veins and nontruncal varicose veins of the legs: a retrospective review of outcomes and adverse effects. Dermatologic surgery 2010; 36 Suppl 2:1026-1033.
52. Pannier-Fischer F, Rabe E. Epidemiology of chronic venous diseases. Der Hautarzt 2003; 54(11): 1037-1044. (Pubitemid 37383860)
53. Parsi K. Paradoxical embolism, stroke and sclerotherapy. Phlebology 2011; 1-21.
54. Picard C et al. Foam sclerotherapy: a possible cause of ischaemic stroke? J Neurol Neurosurg Psychiatry 2010; 81: 582-583.
55. Plas van der JP, Lambers JC et al. Reversible ischaemic neurological deficit after sclerotherapy of varicose veins. Lancet 1994; 8894: 428-428.
56. Rabe E et al. Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial. Eur J Vasc Endovasc Surg 2008; 35(2): 238-245. (Pubitemid 351163086)
57. Ramelet A, Monti M.Phlebologie. Fribourg: Verlag Masson 1988, 1990; 227.
58. Rasmussen LH, Lawaetz M, Bjoern L et al Randomized clinical trial comparing endovenous laser ablation, radiofrequency ablation, foam sclerotherapy and surgical stripping for great saphenous varicose veins. Br J Surg 2011; 98(8): 1079-1087.
59. Raymond-Martimbeau P. Outcomes of Ultrasound-Guided Foam Sclerotherapy for Varicose Veins of the Lower Extremities: Single Center Experience. Dermatol Surg 2011; 37: 810-811.
60. Regan J D et al. Clinical significance of cerebrovascular gas emboli during polidocanol endovenous ultra-low nitrogen microfoam ablation and correlation with magnetic resonance imaging in patients with right-to-left shunt. J Vasc Surg 2011; 53(1): 131-137.
61. Rush JE. More on Microembolism and Foam Sclerotherapy. N Engl J Med 2008; 359: 6.
62. Sarvananthan T, Shepherd AC et al. Neurological complications of sclerotherapy for varicose veins. J Vasc Surg 2011: 1-9.
63. Schuller-Petrovic S, Pavlovic M et al. Subcutaneous injection of liquid and foamed polidocanol: extravasation is not responsible for skin necrosis during reticular and spider vein sclerotherapy. J Europ Acad Derm Ven 2011; 25: 983-986.
64. Shub C et a.l Detecting intrapulmonary right-to-left shunt with contrast echocardiography. Observations in a patient with diffuse pulmonary arteriovenous fistulas. Mayo Clin Proc 1976; 51(2): 81-84.
65. Stautner-Brückmann C Passager. Halbseitensymptomatik nach Schaumsklerotherapie. Vasa 2009; 24: 131-138.
66. Stickland MK et al Intra-pulmonary shunt and pulmonary gas exchange during exercise in humans. J Physiol 2004; 1: 321-329. (Pubitemid 39549487)
67. Svenarud P, Persson M, Linden J van der. Effect of CO2 insufflation on the number and behavior of air microemboli in open-heart surgery: a randomized clinical trial. Circulation 2004; 109(9): 1127-1132. (Pubitemid 38337407)
68. Wandrup JH. Quantifying pulmonary oxygen transfer deficits in critically ill patients. Acta Anaesthesiol Scand Suppl 1995; 107: 37-44.
69. Wollmann JC. Sclerosant foams Stabilities, physical properties and rheological behavior. Phlebologie 2010; 4: 208-217.
70. Wright D, Gobin JP, Bradbury a W et al. Varisolve® polidocanol microfoam compared with surgery or sclerotherapy in the management of varicose veins in the presence of trunk vein incompetence: European randomized controlled trial. Phlebology 2006; 21(4): 180-190. (Pubitemid 44913249)
71. Wright DD. High prevalence of right-to-left shunt in patients with symptomatic great saphenous incompetence and varicose veins. J Vasc Surg 2010; 51(1): 104-107.
72. Yamaki T et al. Comparative study of duplex-guided foam sclerotherapy and duplex-guided liquid sclerotherapy for the treatment of superficial venous insufficiency. Dermatologic surgery 2004; 30(5): 718-722. (Pubitemid 38657962)